YELLOWSTONE BIOSCIENCES

What this means for you

Approved and waiting on proof of use. It will register unless the applicant drops it, and its 03 Apr 2025 filing date already counts against anyone who files later.

Record

Serial number

99119599

Mark type

Stylized text

Filed

03 Apr 2025

Published for opposition

02 Dec 2025

Attorney of record

Catherine Parrish Lake

Goods and services

• Class 005 — Pharmaceuticals: Pharmaceutical preparations and substances for the treatment of cancer; immunotherapy preparations for the treatment of cancer; pharmaceutical and biological preparations and substances for immunotherapy for the treatment of cancer; therapeutic vaccines; genetic medicines for the treatment of cancer; soluble T-cell receptor (TCT) based therapies for the treatment of cancer; diagnostic reagents for medical purposes; synthetic peptides, proteins and cells for pharmaceutical purposes; peptides, proteins and cells for medical, diagnostic or therapeutic purposes; in vitro diagnostic reagents, in vivo diagnostic reagents, immunological reagents for medical use; biological reagents for medical and clinical diagnosis; diagnostic kits comprising medical diagnostic reagents and medical diagnostic tests for use in disease detection, namely, the detection of cancer and cancer cells; biological reagents for medical research; biological reagents for medical use; biological preparations for medical use for the treatment of cancer; immuno-therapeutic agents for medical purposes; antigen binding molecules in the nature of peptides, antibodies, antibody fragments, bi-specific T cell engagers (BiTEs), T cell receptors (TCRs) and chimeric antigen receptors (CARs) for medical purposes and for the treatment of cancer; biotechnological preparations for the treatment of cancer; soluble T-cell receptor (TCR) based therapies for the treatment of cancer; immunotherapy products for use in oncology for the treatment of cancer; therapeutic vaccines for use in oncology for human use for the treatment of cancer; immunotherapy products for use in oncology for human use for the treatment of cancer; T-cell receptors for the treatment of cancer; immunotherapy preparations comprising engineered T-cell receptors for the treatment of cancer; immunotherapy preparations comprising genes encoding engineered T-cell receptors for the treatment of cancer; all of the aforesaid goods only for use in connection with immunotherapy
• Class 042 — Scientific and technological services: Scientific, medical and pharmaceutical research and development services in the field of immunotherapy; pharmaceutical drug development services; research and development of pharmaceutical preparations; chemical, biochemical, biological, immunological and bacteriological research and analysis services; biological research; clinical research in the field of cancer diagnosis, prevention and treatment and the development of pharmaceutical products associated therewith, immunotherapy, immune-therapeutic treatments, therapeutic vaccines, cell therapy and genetic medicines; scientific research in the field of chemistry, biochemistry and biology; services of a biological, biochemical or chemical laboratory for research and for the production of pharmaceutical preparations; performing of biological, biochemical or chemical analysis services; cancer diagnostics for scientific purposes; biological and biochemical examination services, namely, examining biological samples for the purposes of developing cancer diagnosis and prevention methods and treatments in the nature of immunotherapy, immune-therapeutic treatments, therapeutic vaccines, cell therapy and genetic medicines; Laboratory services for the production cancer diagnosis and prevention methods and for the production of cancer related pharmaceuticals in the nature of culturing of cells for others, research and development of new products, testing of pharmaceuticals; Laboratory services for the production of chemotherapy drugs in the nature of culturing of cells for others, research and development of new products, testing of pharmaceuticals; Laboratory services for the production of cancer related vaccines in the nature of culturing of cells for others, research and development of new products, testing of vaccines; development of testing methods for the  production of immunotherapy, immune-therapeutic treatments, therapeutic vaccines, cell therapy and genetic medicines for purposes of cancer diagnosis, prevention and treatment; research, development, technical design, testing, design and development of software in the field of biology; consultancy and analysis services in the field of immuno-therapeutics and in particular immune-oncology; Pharmaceutical product research and development; Biotechnology research and development; vaccine and immunotherapy research and development; research and development services in relation to pharmaceutical preparations and substances; research and development services in relation to pharmaceutical and biological preparations and substances for immunotherapy; research and development services in relation to gene therapy, cell therapy and genetic medicines; pharmaceutical and biological research and development services in connection with the treatment of cancer; research and development services in connection with gene therapy, cell therapy, genetic medicines and soluble T-cell receptor (TCR) based therapies for the treatment of cancer; advice, information and consultancy in connection with all of the aforesaid services; all of the aforesaid services only for use in connection with immunotherapy
• Class 044 — Medical, beauty and agricultural services: Providing a web site featuring medical information; medical counselling and medical information relating to pharmaceuticals, immunotherapy, immune-therapeutic treatments, therapeutic vaccines and genetic medicines; Medical laboratory analysis services relating to the treatment of persons with cancer; Medical analysis services for cancer diagnostic and treatment purposes provided by medical laboratories; providing medical supply for therapy, in particular supply of peptides, proteins or cells for immuno-therapy for others for medical purposes; medical diagnostic services; medical monitoring, testing, inspection and analysis services relating to the diagnosis and treatment by immune-therapeutics; medical and pharmaceutical consultancy; provision of medical information and services in the field of immuno-therapeutics; provision of medical treatment services and medical information services in relation to immuno-therapeutics; provision of medical information via a website

Owner

• Yellowstone Biosciences Limited, Cheshire, GB
• Yellowstone Biosciences Limited, Cheshire, GB

Prosecution history

• 26 Mar 2026 — TEAS DELETE 1(B) BASIS RECEIVED
• 27 Jan 2026 — NOA E-MAILED - SOU REQUIRED FROM APPLICANT
• 02 Dec 2025 — OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
• 02 Dec 2025 — PUBLISHED FOR OPPOSITION
• 26 Nov 2025 — NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
• 05 Nov 2025 — APPROVED FOR PUB - PRINCIPAL REGISTER
• 05 Nov 2025 — EXAMINER'S AMENDMENT ENTERED
• 05 Nov 2025 — NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
• 05 Nov 2025 — EXAMINERS AMENDMENT E-MAILED
• 05 Nov 2025 — EXAMINERS AMENDMENT -WRITTEN
• 23 Oct 2025 — TEAS/EMAIL CORRESPONDENCE ENTERED
• 23 Oct 2025 — CORRESPONDENCE RECEIVED IN LAW OFFICE
• 23 Oct 2025 — TEAS RESPONSE TO OFFICE ACTION RECEIVED
• 03 Sept 2025 — NOTIFICATION OF NON-FINAL ACTION E-MAILED
• 03 Sept 2025 — NON-FINAL ACTION E-MAILED